Observational Study of Oxidative Stress and Inflammation in Gaucher Disease Type I
This study is looking at how oxidative stress (an imbalance between free radicals and antioxidants in your body) and inflammation (your body's response to injury or infection) are involved in Gaucher disease type I. Researchers will measure different markers in your blood to see if they can be used to understand these processes better. You may be able to join if you are an adult with Gaucher disease type I, between 18 and 75 years old, and are medically stable. The study aims to see if changes in specific blood markers, like C5a and Hepcidin, are present after 6 months. The current status of this study is unclear.
- Study design
- This is an observational study planning to enroll 34 participants. It is not testing a new treatment, but rather observing certain health markers.
- What's involved
- You would provide 15 milliliters of blood during three separate visits over approximately 3 months. These samples will be used to measure various biomarkers.
- Compensation
- Not stated in the trial record.
- Follow-up
- Changes in certain blood markers will be measured at 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Oxidative Stress and Inflammatory Biomarkers in Gaucher Disease
At a glance
Conditions
NCT02437396
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of Minnesota
Minneapolis, Minnesotastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Reena Kartha, PhD · PRINCIPAL_INVESTIGATOR · University of Minnesota
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change in Plasma C5a Concentration6 months
Outcome will be reported as the change in plasma concentration of C5a (ng/ml) from baseline to 6 months in participants with Gaucher disease type 1
- Change in Plasma Hepcidin Concentration6 months
Outcome will be reported as the change in plasma concentration of hepcidin (ng/ml) from baseline to 6 months in participants with Gaucher disease type 1